She is a proud Gympie-ite who grew up here and raised four children in the region, is passionate about her hometown, about being a voice and an advocate for its people, and about exposing, debating and resolving the issues facing the region.
Shelley leads the largest and most talented, multi award winning group of reporters in the Gympie region, providing local news 24/7 and giving comprehensive, professional coverage of the local courts, crime, council, schools, business, real estate and daily triumphs, challenges and tragedies that unfold locally.
“Like many of you, I was devastated by last year‘s closure of our print titles including The Gympie Times, and while there’s still print ink flowing in these veins, we must look to the future,” Shelley said.
The change will deliver a faster website, quicker coverage of breaking news across Queensland, Australia and beyond, as well as quick access to Rewards, SuperCoach, and other great features of a statewide website.
Instead of needing to access two websites you are paying for, everything is in one place. One login, one password. The Gympie Times will continue to report on historic events like the protests outside Gympie in December 2020. Pictures: Kristen Camp
What won‘t change is our passion for local news.
Make no mistake, our commitment remains to the readers of The Gympie Times. We work for you, and that won‘t change.
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
January 12, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) Jan 12, 2021
OX2 Therapeutics, Inc., a privately held Minneapolis company, announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors.
“This is a first-of-its kind immunotherapy that works to treat one of the most aggressive and deadly cancers today,” said Christopher Moertel, MD, OX2 Therapeutics, Inc. “Central nervous system cancers are the number one cause of cancer related mortality in children, and a major cause of morbidity and mortality in adults.”
January 7, 2021 Elizabeth Neil
Physicians and scientists at the University of Minnesota have opened a new brain cancer clinical trial and have treated their first patient. This Phase I, first-in-human trial is enrolling patients with a specific type of brain cancer, glioblastoma. The development for this innovative treatment is based on years of research from Michael Olin, PhD, and Christopher Moertel, MD, researchers in the University of Minnesota Medical School’s Division of Hematology and Oncology, Department of Pediatrics, as well as a high-grade canine clinical trial conducted by G. Elizabeth Pluhar, DVM, PhD, DACVS, in the University of Minnesota College of Veterinary Medicine’s Department of Veterinary Clinical Sciences. The researchers are also members of the Masonic Cancer Center, University of Minnesota.